Document is current
Any future updates will be listed below
-
Authors
Lanskey, Juliette H. https://orcid.org/0000-0002-6626-7686
Jafarian, Amirhossein
Hughes, Laura E.
Karadag, Melek
Kocagoncu, Ece
Rouse, Matthew A.
Adams, Natalie E.
Naessens, Michelle
Raymont, Vanessa
Woolrich, Mark https://orcid.org/0000-0001-8460-8854
Singh, Krish D. https://orcid.org/0000-0002-3094-2475
Henson, Richard N. https://orcid.org/0000-0002-0712-2639
Rowe, James B. https://orcid.org/0000-0001-7216-8679
- License Information
-
More Information
Article History
Received: 6 November 2024
Revised: 3 September 2025
Accepted: 23 September 2025
First Online: 10 October 2025
Competing interests
: EK has stock options from Merck & Co, which are unrelated to the current manuscript. JBR receives consultancy fees from Astex, Asceneuron, Alector, Astraonautx, Booster Therapeutics, Ferrer, Eisai, ClinialInk, Prevail, SV Health, Rowe&Rowe consultancy, Curasen, CumulusNeuro, VesperBio which are unrelated to the current work. KDS receives consultancy fees from Draig Therapeutics, which are unrelated to the current work. MW receives FSL royalties and consultancy fees from Wellcome Trust grant funding interview panel, which are unrelated to the current work.
: All methods were performed in accordance with the relevant guidelines and regulations. Approval The studies were approved by the local ethics committee, the East of England Cambridge Central Research Ethics Committee (REC reference 18/EE/0042). Written, informed consent was obtained from all participants.
